Dr. James Neil – University of Glasgow

Below is a transcript of the testimonial from the late Dr. James Neil from the University of Glasgow on his experience publishing the research paper, “Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model,” with Oncotarget.

—

Dr. James Neil

“As a recently established journal, Oncotarget was an unknown quantity for us when we decided to submit our recent manuscript.

The scope was a good fit and recent editions of the journal contained some interesting and good quality papers. We were pleasantly surprised by the speed and efficiency of the peer review process. The selected reviewers were clearly experts in the field, and offered largely positive and constructive comments.

For authors who want to publish in a timely manner and receive a fair value judgement, my experience of Oncotarget has been positive. As our paper was chosen as a Priority Report, I was also asked to take part in a video interview, which proved to be quick and relatively painless way to explain the context and what we believe is the significance of our work for a wider audience.”

Click here to read the full study, published by Oncotarget.

View more testimonials here.

Below: The late Dr. James Neil discusses his paper published by Oncotarget, entitled, “Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model”

ONCOTARGET VIDEOS: YouTube | LabTube | Oncotarget.com

—

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact media@impactjournals.com.